These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19774589)

  • 21. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
    J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
    Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
    ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
    Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors.
    Kumar A; Wang Y; Lin X; Sun G; Parang K
    ChemMedChem; 2007 Sep; 2(9):1346-60. PubMed ID: 17530729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.
    Cozza G; Zanin S; Sarno S; Costa E; Girardi C; Ribaudo G; Salvi M; Zagotto G; Ruzzene M; Pinna LA
    Biochem J; 2015 Nov; 471(3):415-30. PubMed ID: 26349539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
    Duncan JS; Haystead TA; Litchfield DW
    Methods Mol Biol; 2012; 795():119-34. PubMed ID: 21960219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical approaches to reversible protein phosphorylation.
    Cole PA; Courtney AD; Shen K; Zhang Z; Qiao Y; Lu W; Williams DM
    Acc Chem Res; 2003 Jun; 36(6):444-52. PubMed ID: 12809531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in designing substrate-competitive protein kinase inhibitors.
    Han KC; Kim SY; Yang EG
    Curr Pharm Des; 2012; 18(20):2875-82. PubMed ID: 22571656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors influencing the inhibition of protein kinases.
    Brockhoff M; Hau JC; Fontana P; Zimmermann C; Pover AD; Erdmann D; Chène P
    J Enzyme Inhib Med Chem; 2012 Apr; 27(2):194-200. PubMed ID: 21635207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-penetrating bisubstrate-based protein kinase C inhibitors.
    van Wandelen LT; van Ameijde J; Ismail-Ali AF; van Ufford HC; Vijftigschild LA; Beekman JM; Martin NI; Ruijtenbeek R; Liskamp RM
    ACS Chem Biol; 2013 Jul; 8(7):1479-87. PubMed ID: 23621550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel kinase inhibitors by reshuffling ligand functionalities across the human kinome.
    Vidović D; Muskal SM; Schürer SC
    J Chem Inf Model; 2012 Dec; 52(12):3107-15. PubMed ID: 23121521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro protein kinase activity measurement by flow cytometry.
    Bernsteel DJ; Roman DL; Neubig RR
    Anal Biochem; 2008 Dec; 383(2):180-5. PubMed ID: 18796290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 'retro-design' concept for novel kinase inhibitors.
    Müller G; Sennhenn PC; Woodcock T; Neumann L
    IDrugs; 2010 Jul; 13(7):457-66. PubMed ID: 20582870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
    Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
    Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A priori inference of cross reactivity for drug-targeted kinases.
    Fernandez A; Maddipati S
    J Med Chem; 2006 Jun; 49(11):3092-100. PubMed ID: 16722629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MALDI-TOF mass-spectrometry-based versatile method for the characterization of protein kinases.
    Kondo N; Nishimura S
    Chemistry; 2009; 15(6):1413-21. PubMed ID: 19115309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.